Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Needs assessment for creation of a platform trial network in metabolic-dysfunction associated steatohepatitis

  • Sena, Elena|||0000-0003-1220-5639
  • Tacke, Frank|||0000-0001-6206-0226
  • Anstee, Quentin M.|||0000-0002-9518-0088
  • Di Prospero, Nicholas
  • Skalshøi- Kjær, Mette
  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Rivera Esteban, Jesús|||0000-0003-4357-8817
  • Jiménez-Masip, Alba
  • Bañales, Jesús M.
  • Martínez-Gómez, María
  • Koenig, Franz
  • Genescà Ferrer, Joan|||0000-0002-0831-8422
  • Ratziu, Vlad
  • Pericàs, Juan M.|||0000-0002-3645-3293
The EU Patient-cEntric clinicAl tRial pLatforms (EU-PEARL) project (IMI2-853966) aimed to develop tools to establish integrated research platforms (IRP) for conducting adaptive-design trials in various diseases, including metabolic-dysfunction associated steatohepatitis (MASH). One essential component of a successful MASH IRP is a robust and reliable Clinical Research Network (CRN). Herein, we outline the required elements and anticipated steps to set-up such a CRN. We identified European clinical research sites that could potentially serve as the foundation for MASH IRP and a CRN. A survey was sent to sites to assess their interest in joining a CRN, their familiarity with platform trials, and their capacity to participate in a future MASH IRP. A total of 141 investigators were invited to participate in the survey, and 40% responded. More than half of the answers (52%) identify MASH with advanced fibrosis (F3-4) as the subpopulation with the greatest unmet need. Regarding the difficulty in identifying candidates for trials, 65% find it is moderately difficult and 30% very difficult. Most respondents (94%) believe that a platform trial could offer substantial benefits to patients. Nearly all researchers express interest in participating in a platform trial (78%), with 22% indicating their interest would be contingent on initial industry funding. While preliminary, our findings on responding sites are encouraging for the potential establishment of a CRN for a MASH IRP. However, funding schemes and sustainability strategies to provide proof-of-platform in MASH seem key in the short-term scenario. Metabolic dysfunction-associated steatohepatitis (MASH) occurs when the liver becomes damaged due to the build up of fat, which is often related to obesity and diabetes. There is a lack of effective drug treatments for MASH, so strategies to strengthen clinical research in this area are needed. Here, we survey key European experts on MASH to assess their interest in joining a network of MASH researchers and their interest in participating in a new type of clinical trial called a platform trial, where multiple drugs can be tested simultaneously. Researchers largely agree that these are promising approaches to boost drug development in the field, although have concerns regarding funding and sustainability strategies. Our findings may inform the creation of a network of MASH researchers capable of running a platform trial, which in turn may speed up research into treatments for MASH. Sena et al. survey European clinical research sites that could potentially serve as the foundation for a MASH integrated research platform and clinical research network. Respondents generally believe that a MASH platform trial could benefit patients and are interested in participating, though securing industry funding is identified as a priority.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Current state-of-the-art and gaps in platform trials, 10 things you should know, insights from EU-PEARL

  • Koenig, Franz
  • Spiertz, Cécile
  • Millar, Daniel
  • Rodríguez Navarro, Sarai
  • Machín, Núria
  • Van Dessel, Ann
  • Genescà Ferrer, Joan|||0000-0002-0831-8422
  • Pericàs, Juan M.|||0000-0002-3645-3293
  • Posch, Martin
Platform trials bring the promise of making clinical research more efficient and more patient centric. While their use has become more widespread, including their prominent role during the COVID-19 pandemic response, broader adoption of platform trials has been limited by the lack of experience and tools to navigate the critical upfront planning required to launch such collaborative studies. The European Union-Patient-cEntric clinicAl tRial pLatform (EU-PEARL) initiative has produced new methodologies to expand the use of platform trials with an overarching infrastructure and services embedded into Integrated Research Platforms (IRPs), in collaboration with patient representatives and through consultation with U.S. Food and Drug Administration and European Medicines Agency stakeholders. In this narrative review, we discuss the outlook for platform trials in Europe, including challenges related to infrastructure, design, adaptations, data sharing and regulation. Documents derived from the EU-PEARL project, alongside a literature search including PubMed and relevant grey literature (e.g., guidance from regulatory agencies and health technology agencies) were used as sources for a multi-stage collaborative process through which the 10 more important points based on lessons drawn from the EU-PEARL project were developed and summarised as guidance for the setup of platform trials. We conclude that early involvement of critical stakeholder such as regulatory agencies or patients are critical steps in the implementation and later acceptance of platform trials. Addressing these gaps will be critical for attaining the full potential of platform trials for patients.
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Contribución de congreso (ConferenceOutput)

Book of Abstracts XVIII Congreso de Biometría CEBMADRID

  • Cabras, Stefano
  • Cascos Fernández, Ignacio
  • Castellanos, María Eugenia
  • Durbán Reguera, María Luz
Abstracts of the XVIII Congreso de Biometría CEBMADRID held from 25 to 27 May in Madrid, Interactive modelling and prediction of patient evolution via multistate models / Leire Garmendia Bergés, Jordi Cortés Martínez and Guadalupe Gómez Melis : This research was funded by the Ministerio de Ciencia e Innovación (Spain) [PID2019104830RBI00]; and the Generalitat de Catalunya (Spain) [2017SGR622 and 2020PANDE00148]., Operating characteristics of a model-based approach to incorporate non-concurrent controls in platform trials / Pavla Krotka, Martin Posch, Marta Bofill Roig : EU-PEARL (EU Patient-cEntric clinicAl tRial pLatforms) project has received funding from the Innovative Medicines Initiative (IMI) 2 Joint Undertaking (JU) under grant agreement No 853966. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Children’s Tumor Foundation, Global Alliance for TB Drug Development non-profit organisation, Spring works Therapeutics Inc., Modeling COPD hospitalizations using variable domain functional regression / Pavel Hernández Amaro, María Durbán Reguera, María del Carmen Aguilera Morillo, Cristobal Esteban Gonzalez, Inma Arostegui : This work is supported by the grant ID2019-104901RB-I00 from the Spanish Ministry of Science, Innovation and Universities MCIN/AEI/10.13039/501100011033., Spatio-temporal quantile autoregression for detecting changes in daily temperature in northeastern Spain / Jorge Castillo-Mateo, Alan E. Gelfand, Jesús Asín, Ana C. Cebrián / Spatio-temporal quantile autoregression for detecting changes in daily temperature in northeastern Spain : This work was partially supported by the Ministerio de Ciencia e Innovación under Grant PID2020-116873GB-I00; Gobierno de Aragón under Research Group E46_20R: Modelos Estocásticos; and JC-M was supported by Gobierno de Aragón under Doctoral Scholarship ORDEN CUS/581/2020., Estimation of the area under the ROC curve with complex survey data / Amaia Iparragirre, Irantzu Barrio, Inmaculada Arostegui : This work was financially supported in part by IT1294-19, PID2020-115882RB-I00, KK-2020/00049. The work of AI was supported by PIF18/213., INLAMSM: Adjusting multivariate lattice models with R and INLA / Francisco Palmí Perales, Virgilio Gómez Rubio and Miguel Ángel Martínez Beneito : This work has been supported by grants PPIC-2014-001-P and SBPLY/17/180501/000491, funded by Consejería de Educación, Cultura y Deportes (Junta de Comunidades de Castilla-La Mancha, Spain) and FEDER, grant MTM2016-77501-P, funded by Ministerio de Economía y Competitividad (Spain), grant PID2019-106341GB-I00 from Ministerio de Ciencia e Innovación (Spain) and a grant to support research groups by the University of Castilla-La Mancha (Spain). F. Palmí-Perales has been supported by a Ph.D. scholarship awarded by the University of Castilla-La Mancha (Spain).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Impact of the COVID-19 pandemic on the care and outcomes of people with NAFLD-related cirrhosis

  • Rivera-Esteban, Jesús
  • Manzano-Nuñez, Ramiro
  • Broquetas, Teresa
  • Serra-Matamala, Isabel
  • Bassegoda, Octavi
  • Soriano-Varela, Agnès
  • Espín, Gemma
  • Castillo, Joaquín
  • Bañares, Juan
  • Carrión Rodríguez, José Antonio
  • Ginès, Pere
  • Graupera, Isabel
  • Pericàs, Juan
Background & aims: The COVID-19 pandemic has had a major negative impact on health systems and many chronic diseases globally. We aimed to evaluate the impact of the first year of the pandemic on the outcomes of people with NAFLD cirrhosis. Methods: We conducted a before-after study in four University hospitals in Catalonia, Spain. Study subperiods were divided into Pre-pandemic (March/2019-February/2020) vs. Pandemic (March/2020-February/2021). The primary outcome was the rate of first liver-related event (LRE). Overall clinical outcomes (LREs plus cardiovascular plus all-cause mortality) were also assessed. Results: A total of 354 patients were included, all of whom were compensated at the beginning of the study period; 83 individuals (23.5%) had a history of prior hepatic decompensation. Mean age was 67.3 years and 48.3% were female. Median BMI was 31.2 kg/m2 and type 2 diabetes was present in 72.8% of patients. The rates of first LRE in the Pre-pandemic and Pandemic periods were 7.4% and 11.3% (p = 0.12), respectively. Whilst the rate of overall events was significantly higher in the Pandemic period (9.9% vs. 17.8%; p = 0.009), this was strongly associated with COVID-19-related deaths. The rate of worsened metabolic status was significantly higher in the Pandemic period (38.4% vs. 46.1%; p = 0.041), yet this was not associated with the risk of first LRE during the Pandemic period, whereas type 2 diabetes (odds ratio [OR] 3.77; 95% CI 1.15-12.32; p = 0.028), albumin <4 g/L (OR 4.43; 95% CI 1.76-11.17; p = 0.002) and Fibrosis-4 score >2.67 (OR 15.74; 95% CI 2.01-123.22; p = 0.009) were identified as risk factors in the multivariable analysis. Conclusion: Overall, people with NAFLD cirrhosis did not present poorer liver-related outcomes during the first year of the pandemic. Health system preparedness seems key to ensure that people with NAFLD cirrhosis receive appropriate care during health crises.Lay summary: Mobility restrictions and social stress induced by the COVID-19 pandemic have led to increased alcohol drinking and worsened metabolic control (e.g., weight gain, poor control of diabetes) in a large proportion of the population in many countries. We aimed to analyze whether people with cirrhosis due to non-alcoholic fatty liver disease, who are particularly vulnerable to such lifestyle modifications, were significantly impacted during the first year of the pandemic. We compared the clinical situation of 354 patients one year before the pandemic and one year after. We found that although metabolic control was indeed worse after the first year of the pandemic and patients presented worse clinical outcomes, the latter was mostly due to non-liver causes, namely COVID-19 itself. Moreover, the care provided to these patients did not worsen during the first year of the pandemic., TB has received educational and research support from Gilead and Abbvie. JMP reports having received consulting fees from Boehringer Ingelheim and Novo Nordisk. He has received speaking fees from Gilead, and travel expenses from Gilead, Rubió, Pfizer, Astellas, MSD, CUBICIN, and Novo Nordisk. He has received educational and research support from Gilead, Pfizer, Astellas, Accelerate, Novartis, Abbvie, ViiV, and MSD, and funds from European Commission/EFPIA IMI2 853966-2, IMI2 777377, H2020 847989, and ISCIII PI19/01898. Other authors: nothing to disclose. None of the authors have any personal conflict with regards to the present manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Impact of the COVID-19 pandemic on the care and outcomes of people with NAFLD-related cirrhosis

  • Rivera-Esteban, Jesús
  • Manzano-Nuñez, Ramiro
  • Broquetas, Teresa
  • Serra-Matamala, Isabel
  • Bassegoda, Octavi
  • Soriano-Varela, Agnès
  • Espín, Gemma
  • Castillo, Joaquín
  • Bañares, Juan
  • Carrión Rodríguez, José Antonio
  • Ginès, Pere
  • Graupera, Isabel
  • Pericàs, Juan
Background & aims: The COVID-19 pandemic has had a major negative impact on health systems and many chronic diseases globally. We aimed to evaluate the impact of the first year of the pandemic on the outcomes of people with NAFLD cirrhosis. Methods: We conducted a before-after study in four University hospitals in Catalonia, Spain. Study subperiods were divided into Pre-pandemic (March/2019-February/2020) vs. Pandemic (March/2020-February/2021). The primary outcome was the rate of first liver-related event (LRE). Overall clinical outcomes (LREs plus cardiovascular plus all-cause mortality) were also assessed. Results: A total of 354 patients were included, all of whom were compensated at the beginning of the study period; 83 individuals (23.5%) had a history of prior hepatic decompensation. Mean age was 67.3 years and 48.3% were female. Median BMI was 31.2 kg/m2 and type 2 diabetes was present in 72.8% of patients. The rates of first LRE in the Pre-pandemic and Pandemic periods were 7.4% and 11.3% (p = 0.12), respectively. Whilst the rate of overall events was significantly higher in the Pandemic period (9.9% vs. 17.8%; p = 0.009), this was strongly associated with COVID-19-related deaths. The rate of worsened metabolic status was significantly higher in the Pandemic period (38.4% vs. 46.1%; p = 0.041), yet this was not associated with the risk of first LRE during the Pandemic period, whereas type 2 diabetes (odds ratio [OR] 3.77; 95% CI 1.15-12.32; p = 0.028), albumin <4 g/L (OR 4.43; 95% CI 1.76-11.17; p = 0.002) and Fibrosis-4 score >2.67 (OR 15.74; 95% CI 2.01-123.22; p = 0.009) were identified as risk factors in the multivariable analysis. Conclusion: Overall, people with NAFLD cirrhosis did not present poorer liver-related outcomes during the first year of the pandemic. Health system preparedness seems key to ensure that people with NAFLD cirrhosis receive appropriate care during health crises.Lay summary: Mobility restrictions and social stress induced by the COVID-19 pandemic have led to increased alcohol drinking and worsened metabolic control (e.g., weight gain, poor control of diabetes) in a large proportion of the population in many countries. We aimed to analyze whether people with cirrhosis due to non-alcoholic fatty liver disease, who are particularly vulnerable to such lifestyle modifications, were significantly impacted during the first year of the pandemic. We compared the clinical situation of 354 patients one year before the pandemic and one year after. We found that although metabolic control was indeed worse after the first year of the pandemic and patients presented worse clinical outcomes, the latter was mostly due to non-liver causes, namely COVID-19 itself. Moreover, the care provided to these patients did not worsen during the first year of the pandemic., TB has received educational and research support from Gilead and Abbvie. JMP reports having received consulting fees from Boehringer Ingelheim and Novo Nordisk. He has received speaking fees from Gilead, and travel expenses from Gilead, Rubió, Pfizer, Astellas, MSD, CUBICIN, and Novo Nordisk. He has received educational and research support from Gilead, Pfizer, Astellas, Accelerate, Novartis, Abbvie, ViiV, and MSD, and funds from European Commission/EFPIA IMI2 853966-2, IMI2 777377, H2020 847989, and ISCIII PI19/01898. Other authors: nothing to disclose. None of the authors have any personal conflict with regards to the present manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Community engagement in tuberculosis research: the EU-Patient-cEntric clinicAl tRial pLatforms (EU-PEARL) experience

  • Saluzzo, Francesca
  • Espinosa-Pereiro, Juan
  • Dressler, Stephan
  • TAVORA DOS SANTOS FILHO, Ezio
  • Seidel, Stephanie
  • Gonzalez Moreno, Jesus
  • SÁNCHEZ-MONTALVÁ, ADRIÁN
Community engagement; Tuberculosis research, Participación de la comunidad; Investigación de la tuberculosis, Compromís comunitari; Recerca en tuberculosi, Objectives: Community representatives are key to ensuring that tuberculosis (TB) research is relevant, culturally sensitive, and appropriate. For all trials (new drugs or treatment regimens, diagnostics, or vaccines) this can result in improvement of recruitment, retention, and adherence to the trial schedule. The early engagement of the community will, later in time, support the process of implementation of new policies designed for successful products. We aim at developing a structured protocol for the early engagement of TB community representatives developed in the context of the EU-Patient-cEntric clinicAl tRial pLatforms (EU-PEARL) project. Design: The EU-PEARL Innovative Medicine Initiative 2 (IMI2) project TB work package has developed a community engagement (CE) framework to ensure fair and efficient participation of the community in the design and implementation of TB clinical platform trials. Results: We showed that early engagement of the EU-PEARL community advisory board highly contributes to the process of development of a community-acceptable Master Protocol Trial and Intervention-Specific Appendixes. We identified capacity building and training as major gaps in advancing CE in the TB field. Conclusion: Developing strategies to address these needs can contribute to preventing tokenism and increase the acceptability and appropriateness of TB research., This work is partially supported by EU-PEARL. EU-PEARL has received funding from the InnovativeMedicines Initiative 2 Joint Undertaking under grant agreement No 853966. This Joint Undertaking receivessupport from the European Union’s Horizon 2020 research and innovation program and EFPIA and Children’sTumor Foundation, Global Alliance for TB Drug Development non-profit organization, SpringworksTherapeutics Inc. This publication reflects the authors’ views. Neither IMI nor the European Union,EFPIA,or any Associated Partners are responsible for any use that may be made of the information contained hereinDMC is the co-leader of EU-PEARL WP5. ASM is supported by a Juan Rodés (JR18/00022) postdoctoral fellowship from ISCIII. FS salary is supported by EU-PEARLgrant to UniSR.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Risk of infections in patients with NAFLD and Type 2 Diabetes under treatment with SGLT2 inhibitors and relationship with liver outcomes, A retrospective case-control study

  • Bañares, Juan|||0000-0002-1966-1947
  • Manzano-Nuñez, Ramiro|||0000-0001-7444-9634
  • Prió, Alba
  • Rivera Esteban, Jesús|||0000-0003-4357-8817
  • Camps-Relats, Laura
  • Villarejo Jiménez, Ana|||0009-0005-7996-9387
  • Ruiz-Ortega, Lourdes|||0000-0003-3636-3367
  • Pons Delgado, Mònica|||0000-0002-0985-3320
  • Ciudin, Andreea|||0000-0001-5622-0203
  • Salcedo, Maria-Teresa|||0000-0002-4822-5060
  • Vargas Blasco, Víctor|||0000-0002-7190-6948
  • Genescà Ferrer, Joan|||0000-0002-0831-8422
  • Pericàs, Juan M.|||0000-0002-3645-3293
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease in developed countries, with its incidence growing parallel to the epidemics of obesity and type 2 diabetes mellitus (T2DM). Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are becoming a cornerstone in the management of cardiovascular health and some studies suggest the potential role in NAFLD. However, patients under treatment with SGLT2i are at risk of developing genitourinary fungal infections (GFIs). Moreover, both NAFLD and SGLT2i have a strong influence on the immune system, and therefore the risk of infections other than GFIs could be increased in NAFLD patients treated with SGLT2i. We aimed to examine the possible association of SGLT2i with infections and hepatic outcomes in NAFLD patients. We conducted a case-control study including NAFLD patients with T2DM visited at the Liver Unit outpatient clinic from 2016 to 2021 with a minimum follow-up of 6 months by selecting 65 patients receiving SGLT2i and 130 matched patients with other types of antidiabetic treatment. During follow-up, GFIs were significantly higher in the SGLT2i group (15.4% vs. 3.8%; p=0.008), whereas there were no differences in the occurrence of overall infections (41.5% vs. 30%; p=0.1) nor in other types of specific infections. In the multivariable analysis, treatment with SGLT2i was not independently associated with higher odds of overall infection. On the other hand, SGLT2i patients showed a significantly lower incidence of hepatic events (1.5% vs. 10.7%; p=0.02). There were no significant different in all-cause mortality between cases and controls. NAFLD patients with T2DM receiving SGLT2i more frequently presented GFIs, whereas the incidence of other types of infections was not found to be higher than in other patients with NAFLD and T2DM treated with other drugs. Moreover, SGLT2i-treated patients had a lower occurrence of hepatic events. Further studies are warranted to validate our data.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Community engagement in tuberculosis research: the EU-Patient-cEntric clinicAl tRial pLatforms (EU-PEARL) experience

  • Saluzzo, Francesca
  • Espinosa-Pereiro, Juan
  • Dressler, Stephan
  • TAVORA DOS SANTOS FILHO, Ezio
  • Seidel, Stephanie
  • Gonzalez Moreno, Jesus
  • SÁNCHEZ-MONTALVÁ, ADRIÁN
Community engagement; Tuberculosis research, Participación de la comunidad; Investigación de la tuberculosis, Compromís comunitari; Recerca en tuberculosi, Objectives: Community representatives are key to ensuring that tuberculosis (TB) research is relevant, culturally sensitive, and appropriate. For all trials (new drugs or treatment regimens, diagnostics, or vaccines) this can result in improvement of recruitment, retention, and adherence to the trial schedule. The early engagement of the community will, later in time, support the process of implementation of new policies designed for successful products. We aim at developing a structured protocol for the early engagement of TB community representatives developed in the context of the EU-Patient-cEntric clinicAl tRial pLatforms (EU-PEARL) project. Design: The EU-PEARL Innovative Medicine Initiative 2 (IMI2) project TB work package has developed a community engagement (CE) framework to ensure fair and efficient participation of the community in the design and implementation of TB clinical platform trials. Results: We showed that early engagement of the EU-PEARL community advisory board highly contributes to the process of development of a community-acceptable Master Protocol Trial and Intervention-Specific Appendixes. We identified capacity building and training as major gaps in advancing CE in the TB field. Conclusion: Developing strategies to address these needs can contribute to preventing tokenism and increase the acceptability and appropriateness of TB research., This work is partially supported by EU-PEARL. EU-PEARL has received funding from the InnovativeMedicines Initiative 2 Joint Undertaking under grant agreement No 853966. This Joint Undertaking receivessupport from the European Union’s Horizon 2020 research and innovation program and EFPIA and Children’sTumor Foundation, Global Alliance for TB Drug Development non-profit organization, SpringworksTherapeutics Inc. This publication reflects the authors’ views. Neither IMI nor the European Union,EFPIA,or any Associated Partners are responsible for any use that may be made of the information contained hereinDMC is the co-leader of EU-PEARL WP5. ASM is supported by a Juan Rodés (JR18/00022) postdoctoral fellowship from ISCIII. FS salary is supported by EU-PEARLgrant to UniSR.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Otros (Other)

Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpoints [dades primàries]

  • Meyer, Elias Laurin
  • Mesenbrink, Peter
  • Di Prospero, Nicholas A.
  • Pericàs Pulido, Juan Manuel
  • Glimm, Ekkehard
  • Ratziu, Vlad
  • De Sena Fernandez, Elena
  • König, Franz
Simulated data; Results, Datos simulados; Resultados, Dades simulades; Resultats, Platform trials in NASH provide great benefits for sponsors and trial participants in terms of accelerating drug development programs. It contains the results of a simulation study. Includes S1 Table Simulated data used for results., Els assaigs de plataforma en NASH ofereixen grans beneficis per als patrocinadors i els participants pel que fa a l'acceleració dels programes de desenvolupament de medicaments. Es presenten els resultats d'un estudi de simulació. Inclou Taula S1 Dades simulades utilitzades per als resultats., Los ensayos de plataforma en NASH ofrecen grandes beneficios para los patrocinadores y los participantes en términos de aceleración de los programas de desarrollo de fármacos. Se presentan los resultados de un estudio de simulación. Incluye Tabla S1 Datos simulados utilizados para los resultados., EU-PEARL has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853966-2. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and CHILDREN’S TUMOR FOUNDATION, GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT NON PROFIT ORGANISATION, SPRINGWORKS THERAPEUTICS INC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.